CeGaT

As part of the collaboration, B. Braun China founded a subsidiary, called B. Braun Precision Medicine Technology (BBPM), that opened in Shanghai in May.

The German company validated the panel, which focuses on actionable results, in a 300-participant clinical study in collaboration with Robert-Bosch-Hospital in Stuttgart.

With the new certification in hand, the company plans to expand its business in the US through its Pennsylvania-based subsidiary, B. Braun CeGaT.

The money will support efforts by the company to develop liquid biopsy methods that can serve patients that its current tissue-based testing does not.

Revisions to the reimbursement catalog went into effect July 1, but stakeholders are quarreling about a pre-authorization requirement in court.

Over the last half year, CeGaT lowered turnaround times and prices for its assays, and its lab recently passed CAP inspection.

A medical genetics practice's lawsuit against a government insurance administrator points to continued uncertainty about reimbursement for NGS testing in Germany.

Cenata, based in Tübingen, has run more than 1,000 samples since it started offering the Harmony test in May.

NEW YORK (GenomeWeb) – N-of-One said this week that it has been selected by CeGaT to provide interpret data from its next-generation sequencing-based oncology tests.

NEW YORK (GenomeWeb) – B. Braun CeGaT, the recently-founded US subsidiary of German genetic diagnostics firm CeGaT and its minority stakeholder B. Braun, will initially offer molecular diagnostic testing services through CeGaT's German laboratory but plans to establish a US lab in the long run.

Pages

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.